NCT07106723招募中2 期
A Clinical Study of the Safety and Efficacy of Autologous Hematopoietic Stem Cell Transplantation in Combination With CD7-CART in the Treatment of CD7+ T-Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2025年6月1日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- PFS rate at 1 year after ASCT conbined with CD7-CART
研究概览
简要总结
To evaluate the safety and efficacy of autologous hematopoietic stem cell transfer (ASCT) combined with CD7-CART in the treatment of CD7+ TCL
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •With the subject's consent and having signed the informed consent form, willing and capable of adhering to the planned visits, study treatment, laboratory tests and other trial procedures;
- •Age 18 to 65 years old, both male and female;
- •Confirmed as T-cell non-Hodgkin's lymphoma type (including T-lymphoblastic lymphoma/leukemia) according to the World Health Organization's classification of hematopoietic and lymphoid tissue tumors (2022), and meeting one of the following three conditions: 1) Newly diagnosed with high-risk factors, such as Ann Arbor stage III/IV, large mass, bone marrow invasion, central nervous system (CNS) invasion, ETP phenotype, RAS activating mutation, TP53 deletion/mutation, etc., as assessed by the investigator; 2) Not achieving PR or better response after induction and consolidation therapy; 3) Patients not considered for allogeneic hematopoietic stem cell transplantation;
- •Confirmed as tumor cells expressing CD7 by histopathology and/or cytology at the time of screening;
- •With appropriate organ function: 1) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal (ULN), if the investigator determines that the abnormal ALT and AST are due to the disease (such as liver infiltration or bile duct obstruction), the indicators can be relaxed to ≤ 5 times ULN; 2) Total serum bilirubin ≤ 2 times ULN, except for patients with Gilbert's syndrome; patients with Gilbert's syndrome and total bilirubin ≤ 3 times ULN and direct bilirubin ≤ 1.5 times ULN can be included; 3) Serum creatinine clearance rate ≥ 30 mL/min; 4) International normalized ratio (INR) ≤ 1.5 times ULN, and activated partial thromboplastin time (aPTT) ≤ 1.5 times ULN; 5) Possessing the minimum level of lung reserve, defined as ≤ grade 1 dyspnea (CTCAE v5.0) and non-oxygen-dependent blood oxygen saturation ≥ 92%; 6) Left ventricular ejection fraction ≥ 50% by echocardiography; no clinically significant abnormal electrocardiogram findings; no clinically significant pericardial effusion and pleural effusion.
- •Women of childbearing age have a negative blood/urine pregnancy test within 7 days before infusion. Any male and female patients with fertility must agree to use effective contraceptive methods throughout the study and for at least 2 years after the administration of study treatment.
排除标准
- •Subjects with one or more of the following are not eligible for this study:
- •History of allergy to any of the components in the cell product;
- •Severe cardiac disease, including but not limited to: Myocardial infarction, cardiac angioplasty, or stenting within 6 months prior to signing the ICF; unstable angina; severe cardiac arrhythmias; History of severe non-ischemic cardiomyopathy; Congestive heart failure (New York Heart Association [NYHA] Class III or IV), NYHA score listed in Appendix II
- •Have a history of autologous/allogeneic hematopoietic stem cell transplantation;
- •stroke or seizure within 6 months prior to signing the ICF;
- •Have autoimmune diseases, immunodeficiencies or other diseases that require immunosuppressant treatment;
- •Within 3 years prior to signing the ICF, have malignancies other than T-cell hematologic tumors, except for adequately treated carcinoma in situ of the cervix, basal cell or squamous epithelial cell skin cancer, localized prostate cancer after radical resection, carcinoma in situ of the duct in situ after radical resection, carcinoma in situ of other sites one year after radical resection, and there has been no treatment during the screening period and there is no sign of recurrence;
- •presence of uncontrolled active infection;
- •Unstable systemic diseases judged by the investigator: including but not limited to severe hepatic, renal or metabolic diseases requiring drug treatment;
- •Any of the following within 4 weeks prior to lymphocyte collection:
- •The DNA detection value of hepatitis B virus (HBV) in peripheral blood was higher than the lower limit of detection; Positive for hepatitis C virus (HCV) antibody and positive for peripheral HCV-RNA; positive for human immunodeficiency virus (HIV) antibodies; positive for syphilis antigen or antibody; Positive for CMV-DNA (10) application of prednisone (or equivalent amounts of other corticosteroids) in excess of 5mg/day within 1 week prior to lymphocyte collection; (11) Have used any CAR-T cell products or other genetically modified T-cell therapies; (12) Received CD7-targeted therapy; (13) History of live vaccination within 4 weeks prior to signing the ICF; (14) Have a history of alcoholism, drug abuse, or mental illness; (15) Other situations that the investigator considers unsuitable to participate in this study.
研究组 & 干预措施
ASCT conbined with CD7-CART.
Experimental
干预措施: ASCT+CD7-CART (Drug)
结局指标
主要结局
PFS rate at 1 year after ASCT conbined with CD7-CART
时间窗: at 1 year after ASCT conbined with CD7-CART
Incidence and Severity of Adverse Events after ASCT conbined with CD7-CART
时间窗: during 2 years after ASCT conbined with CD7-CART
Refer to irAE grading standard
次要结局
- Cmax(during 3 month after ASCT conbined with CD7-CART)
- MRD negetive rate(at 3 or 6 month after ASCT conbined with CD7-CART)
- Duration of Response (DOR)(during 2 years after ASCT conbined with CD7-CART)
- Progression-free Survival (PFS)(during 2 years after ASCT conbined with CD7-CART)
- AUC(0-28d)(during 28 days after ASCT conbined with CD7-CART)
- Time to Response (TTR)(during 2 years after ASCT conbined with CD7-CART)
- Overall Survival (OS)(during 2 years after ASCT conbined with CD7-CART)
- Tmax(during 3 month after ASCT conbined with CD7-CART)
- Tlast(during 1 year after ASCT conbined with CD7-CART)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia ALLNCT06608342Institute of Hematology & Blood Diseases Hospital, China20
招募中
1 期
AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple MyelomaMultiple MyelomaNCT05740891Zhejiang University50
招募中
早期 1 期
Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant LymphomaLymphomaNCT05239676Zhejiang University50
招募中
1 期
ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)Multiple MyelomaNCT05632380Institute of Hematology & Blood Diseases Hospital, China20
已完成
不适用
EBMT ADWP Prospective Non Interventional Study : AutoHSCT in SSc PatientsAutoimmune DiseasesNCT02516124European Society for Blood and Marrow Transplantation82